Accelovance Acquires European CRO

Published on: 

Applied Clinical Trials

Accelovance, Inc. , a CRO therapeutically aligned in the areas of Oncology, Vaccines, and General Medicine; today announced it has acquired Altair Clinical, Ltd.

Accelovance, a therapeutically aligned CRO in the areas of oncology, vaccines, and general medicine; announced it has acquired Altair Clinical, a full service European clinical CRO and provider of global clinical CRO resourcing solutions to pharmaceutical, biotech, and medical device companies. The acquisition expands Accelovance's existing US and Beijing, China offices to include Cambridge, UK, Moscow, Russia, and staff located throughout Europe including Central and Eastern Europe (CEE) and the Middle East and North Africa (MENA). 



Read the full release here.